Terms: = Bone cancer AND KMT2C, ENSG00000055609, MLL3, 58508
12 results:
1. Osteosarcoma's genetic landscape painted by genes' mutations.
Urban W; Krzystańska D; Piekarz M; Nazar J; Jankowska A
Acta Biochim Pol; 2023 Sep; 70(3):671-678. PubMed ID: 37717265
[TBL] [Abstract] [Full Text] [Related]
2. kmt2c mutation in a Chinese man with primary multidrug-resistant metastatic adenocarcinoma of rete testis: a case report.
Zhang Y; He X; Gao H
BMC Urol; 2022 Aug; 22(1):123. PubMed ID: 35945529
[TBL] [Abstract] [Full Text] [Related]
3. Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma.
Zhang L; Zhang R; Wang J; Chen Y; Qiao C; Shi Q; Jin Y; Shen X; Li J; Chen L
Clin Epigenetics; 2022 Jul; 14(1):93. PubMed ID: 35870987
[TBL] [Abstract] [Full Text] [Related]
4. A Multicentre Clinical Study of Sarcoma Personalised Treatment Using Patient-Derived Tumour Xenografts.
Xu H; Zheng H; Zhang Q; Song H; Wang Q; Xiao J; Dong Y; Shen Z; Wang S; Wu S; Wei Y; Lu W; Zhu Y; Niu X
Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):e48-e59. PubMed ID: 35781406
[TBL] [Abstract] [Full Text] [Related]
5. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
[TBL] [Abstract] [Full Text] [Related]
6. Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature.
Liao C; Hu NX; Song H; Zhang JY; Shen DY; Xu XJ; Tang YM
Int J Hematol; 2021 May; 113(5):751-759. PubMed ID: 33392975
[TBL] [Abstract] [Full Text] [Related]
7. kmt2c modulates migration and invasion processes in osteosarcoma cell lines.
Chiappetta C; Carletti R; Della Rocca C; Di Cristofano C
Pathol Res Pract; 2019 Oct; 215(10):152534. PubMed ID: 31337554
[TBL] [Abstract] [Full Text] [Related]
8. Uncommon somatic mutations in metastatic NUT midline carcinoma.
Cavalieri S; Stathis A; Fabbri A; Sonzogni A; Perrone F; Tamborini E; Pelosi G; de Braud F; Platania M
Tumori; 2017 Nov; 103(Suppl. 1):e5-e8. PubMed ID: 28967088
[TBL] [Abstract] [Full Text] [Related]
9. Clinical impact of kmt2c and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients.
Kayser S; Feszler M; Krzykalla J; Schick M; Kramer M; Benner A; Thol F; Platzbecker U; Müller-Tidow C; Ho AD; Ehninger G; Heuser M; Schlenk RF; Thiede C; Röllig C; Krämer A
Eur J Haematol; 2017 Dec; 99(6):544-552. PubMed ID: 28940816
[TBL] [Abstract] [Full Text] [Related]
10. Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis.
Yang W; Ernst P
Curr Opin Hematol; 2017 Jul; 24(4):322-328. PubMed ID: 28375985
[TBL] [Abstract] [Full Text] [Related]
11. Mutational landscape of aggressive cutaneous squamous cell carcinoma.
Pickering CR; Zhou JH; Lee JJ; Drummond JA; Peng SA; Saade RE; Tsai KY; Curry JL; Tetzlaff MT; Lai SY; Yu J; Muzny DM; Doddapaneni H; Shinbrot E; Covington KR; Zhang J; Seth S; Caulin C; Clayman GL; El-Naggar AK; Gibbs RA; Weber RS; Myers JN; Wheeler DA; Frederick MJ
Clin Cancer Res; 2014 Dec; 20(24):6582-92. PubMed ID: 25303977
[TBL] [Abstract] [Full Text] [Related]
12. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders.
Rowley JD; Reshmi S; Sobulo O; Musvee T; Anastasi J; Raimondi S; Schneider NR; Barredo JC; Cantu ES; Schlegelberger B; Behm F; Doggett NA; Borrow J; Zeleznik-Le N
Blood; 1997 Jul; 90(2):535-41. PubMed ID: 9226152
[TBL] [Abstract] [Full Text] [Related]
